Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06846606 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
A Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML, sponsored by Auron Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 9
- Study locations
NCT06846606: Active Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML, sponsored by Auron Therapeutics.
NCT06846606 is a Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML that is active but no longer recruiting, run by Auron Therapeutics. The registered enrollment target is 34 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower). The trial reports 9 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06846606, a Phase 1 study of Refractory Myelodysplastic Syndromes and Relapsed/Refractory AML, is active but no longer recruiting, sponsored by Auron Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 9
- Study locations
Study Summary
This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
Primary Outcome
To assess the safety and tolerability of AUTX-703 by evaluating the incidence and severity of AEs, DLTs, SAEs, and AEs leading to treatment discontinuation.
Conditions Studied
Interventions
- DRUG AUTX-703
Study Locations (9)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
California
- City of Hope National Medical Center - Duarte
Florida
- H Lee Moffitt Cancer Center and Research Institute - Tampa
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Ohio
- Ohio State University, The James Comprehensive Cancer - Columbus
Pennsylvania
- UPENN Perelman Center for Advanced Medicine - Philadelphia
Tennessee
- Sarah Cannon Center for Blood Cancer at TriStar Centennia - Nashville
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2028-06 |
| Phase | Phase 1 |
What the registry record for NCT06846606 still lists
NCT06846606 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (43% lower).
The record links to 6 conditions, with Refractory Myelodysplastic Syndromes appearing as the primary indexed condition, and to 1 intervention - of which AUTX-703 is the first listed.
NCT06846606 lists 9 locations in 8 states (New York, California, Florida).
Frequently Asked Questions
What is clinical trial NCT06846606 about?
NCT06846606 is a clinical study titled "Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS". This Phase 1, multicenter, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of AUTX-703 administered orally in subjects with advanced hematologic malignancies.
What is the current status of trial NCT06846606?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2025-05-01. Estimated completion is 2028-06.
What conditions does trial NCT06846606 study?
This clinical trial studies the following conditions: Refractory Myelodysplastic Syndromes, Relapsed/Refractory AML, Relapsed Myelodysplastic Syndromes, Relapsed Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML).
What interventions are being tested in trial NCT06846606?
The interventions under investigation include: AUTX-703 (DRUG).
Who is sponsoring clinical trial NCT06846606?
This trial is sponsored by Auron Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06846606 being conducted?
This trial has 9 study locations across California, Florida, New York, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Myelodysplastic Syndromes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06846606's enrollment target sits among peer trials
34 1273rd of 2000 higher than 721 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI